Splenomegaly and progressive neurologic involvement: Think about Niemann–Pick type C disease
Pediatrics International · 2024
DOI: 10.1111/ped.15832 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatrics International, 2024. Verfasst von Merve Yoldas Celik und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical Faculty, Department of Pediatric Metabolism and Nutrition, Ege University, Izmir, Türkiye. Hauptthemen laut MEDLINE: Niemann-Pick Disease, Type C, Splenomegaly. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
Background
Niemann–Pick type C (NPC) disease is a lysosomal storage disease with visceral organ involvement and neurological and psychiatric symptoms. This study presents the clinical and laboratory findings of NPC cases involving three novel variants.
Methods
The clinical and laboratory findings were reviewed retrospectively between February 2006 and December 2022.
Results
There were nine females and five males. The median age of diagnosis of the patients was 5 months (range: 1 month to 38 years). The clinical phenotypes of the patients were early infantile ( n = 7), late infantile ( n = 4), juvenile ( n = 2), and adult ( n = 1). The visceral findings were splenomegaly (100%), hepatomegaly (78.6%), neonatal jaundice (42.8%), and hepatic failure (14.3%). The neurological findings were developmental delay (71.4%), seizures (50%), vertical supranuclear gaze palsy (28.6%), ataxia (28.6%), dysarthria (28.6%), dysphagia (21.4%), dystonia (21.4%). Cataplexy (14.3%) and psychiatric manifestations (14.3%) were recorded in juvenile and adult‐onset patients. Three novel variants were detected (p.Asn524LysfsTer39, p.Val1023Phe, and p.Asn906Tyr). Miglustat treatment was received by 64.3% of patients but had no clear effect on the disease course. The median duration of use was 3 years (with a range from 1–13 years). Miglustat's adverse effects were low platelet count (35.7%) and diarrhea (7.1%).
Conclusions
Niemann–Pick type C disease should be considered in the presence of visceral organ involvement and progressive neurological findings. It is essential to support the diagnosis with laboratory and genetic analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Faculty, Department of Pediatric Metabolism and Nutrition, Ege University, Izmir, Türkiye.
- Medical Faculty, Department of Medical Biochemistry, Ege University, Izmir, Türkiye.
- Medical Faculty, Department of Medical Genetics, Ege University, Izmir, Türkiye.
ORCID-Profile: Merve Yoldas Celik, Ebru Canda
Zitieren
APA
Yoldas Celik, M., Yazici, H., Erdem, F., Yuksel Yanbolu, A., Canda, E., Sezer, E., Kalkan Ucar, S., Onay, H., Ozkinay, F., Yildirim Sozmen, E., & Coker, M. (2024). Splenomegaly and progressive neurologic involvement: Think about Niemann–Pick type C disease. Pediatrics International. https://doi.org/10.1111/ped.15832
Vancouver
Yoldas Celik M, Yazici H, Erdem F, Yuksel Yanbolu A, Canda E, Sezer E, et al. Splenomegaly and progressive neurologic involvement: Think about Niemann–Pick type C disease. Pediatrics International. 2024. doi:10.1111/ped.15832
BibTeX
@article{YoldasCelik2024,
author = {Yoldas Celik, Merve and Yazici, Havva and Erdem, Fehime and Yuksel Yanbolu, Ayse and Canda, Ebru and Sezer, Ebru and Kalkan Ucar, Sema and Onay, Huseyin and Ozkinay, Ferda and Yildirim Sozmen, Eser and Coker, Mahmut},
title = {Splenomegaly and progressive neurologic involvement: Think about Niemann–Pick type C disease},
journal = {Pediatrics International},
year = {2024},
doi = {10.1111/ped.15832}
}
EUVIMED